Sign up
Log in
U.S. RESEARCH ROUNDUP-Adapthealth, Carnival, Phunware
Share
Listen to the news
U.S. RESEARCH ROUNDUP-Adapthealth, Carnival, Phunware

- Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Adapthealth, Carnival and Phunware, on Monday.


HIGHLIGHTS


* Adapthealth Corp AHCO.O: Leerink Partners cuts target price to $13 from $14

* Ardent Health Partners Inc ARDT.N: JP Morgan raises target price to $19 from $18

* Carnival Corp CCL.N: HSBC raises target price to $14 from $13

* Miniso Group Holding Ltd MNSO.N: JP Morgan cuts target price to $27 from $29

* Phunware Inc PHUN.O: Ascendiant Capital Markets cuts target price to $20 from $22

Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order.


* Adapthealth Corp AHCO.O: Leerink Partners cuts target price to $13 from $14

* Aemetis Inc AMTX.O: Ascendiant Capital Markets cuts target price to $19 from $20

* Aerovironment Inc AVAV.O: RBC raises target price to $230 from $200

* Aim Immunotech Inc AIM.A: Ascendiant Capital Markets cuts PT to $5 from $5.25

* Ardent Health Partners Inc ARDT.N: JP Morgan raises target price to $19 from $18

* Carnival Corp CCL.N: HSBC raises target price to $14 from $13

* CF Industries Holdings Inc CF.N: Berenberg raises target price to $69 from $67

* Ferrari RACE.N: Bernstein raises target price to $599 from $488

* IGC Pharma Inc IGC.A: Ascendiant Capital Markets raises PT to $3.75 from $3.5

* Miniso Group Holding Ltd MNSO.N: JP Morgan cuts target price to $27 from $29

* Outlook Therapeutics Inc OTLK.O: Ascendiant Capital Markets cuts PT to $33 from $35

* Phunware Inc PHUN.O: Ascendiant Capital Markets cuts target price to $20 from $22

* Plus Therapeutics Inc PSTV.O: Ascendiant Capital Markets cuts PT to $20 from $21

* T-Mobile TMUS.O: Bernstein raises target price to $220 from $190



(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.